Gsa Capital Partners LLP 89bio, Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$15.06 - $19.41 $332,073 - $427,990	22,050 New	22,050 $340,000
Q1 2023 May 12, 2023	SELL	$10.48 - $16.94 $341,616 - $552,193	-32,597 Reduced 68.4%	15,056 $229,000
Q4 2022 Feb 13, 2023	BUY	$5.52 - $12.73 $263,044 - $606,622	47,653 New	47,653 $607,000
Q2 2022 Aug 09, 2022	SELL	$2.09 - $4.02 $193,983 - $373,116	-92,815 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$3.45 - $14.99 $164,285 - $713,808	47,619 Added 105.36%	92,815 $350,000
Q4 2021 Feb 14, 2022	BUY	$11.15 - $19.66 $196,964 - $347,293	17,665 Added 64.16%	45,196 $591,000
Q3 2021 Nov 12, 2021	BUY	$14.91 - $21.31 $410,487 - $586,685	27,531 New	27,531 $539,000
Q2 2021 Aug 05, 2021	SELL	$17.42 - $28.0 $309,396 - $497,308	-17,761 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$20.22 - $26.73 $121,057 - $160,032	5,987 Added 50.85%	17,761 $421,000
Q4 2020 Feb 03, 2021	BUY	$23.16 - $28.08 $272,685 - $330,613	11,774 New	11,774 $287,000

167

109M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $530M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.